ANG Lifesciences India Limited

Healthcare · Pharmaceuticals & Biotechnology

BSE: 540694
₹41.00
▲ 0.75 (1.86%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
22/100
Weak
Valuation
—/100
Data unavailable
Momentum
73/100
Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
Data unavailable.
PE (TTM)
Data unavailable.
Price to Book
Data unavailable.
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-8.2
Free Cash Flow
₹11 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-338.98%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
55.56%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-17.54%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
25.51%
as of Sept. 30, 2025
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-43.10%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
0.97
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
1.47
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
-0.31
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
4.84%
as of March 31, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
-19.63%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
-2.54%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
-2.81%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
1.92%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
-8.58%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Debt to equity is below 0.5 (1.47)
  • No Return on equity is 15% or more (-8.6%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

1 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

2 of 4 met
  • Yes Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
1.9%
Low 40.2500 · High 41.0500
1W return
5.9%
Low 39.3900 · High 41.0700
1M return
26.9%
Low 31.9000 · High 41.0700
52W return
-8.2%
Low 23.1300 · High 41.0700
Lifetime High ₹762.3500 (Nov. 8, 2021)
Lifetime Low ₹24.3400 (Aug. 21, 2026)

Full price history and technicals →

EMA & SMA

Bullish4
Bearish2
5D
40.3
10D
39.2
20D
37.7
50D
39.0
100D
44.7
200D
55.8

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
100.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

40.77
Pivot
First resistance41.28
Second resistance41.57
Third resistance42.08
First support40.48
Second support39.97
Third support39.68
Day RSI69.0
Day MFI95.9
Day MACD1.40
Day MACD signal0.70

Beta

1M-0.47
3M-0.30
1Y-0.30
3Y0.07

Price change analysis

↑ 26.9%
Over 1 Month
LowHigh
31.9041.07
↓ -8.2%
Over 3 Months
LowHigh
23.1341.07
↓ -8.2%
Over 6 Months
LowHigh
23.1341.07
↓ -8.2%
Over 1 Year
LowHigh
23.1341.07
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Revenue (June 30, 2026)
₹14 Cr
Net profit (June 30, 2026)
₹— Cr
Basic EPS (June 30, 2026)
₹-2.5900

Ranks #None of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Mar 2026
  • Promoter70.60%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 70.60% in Mar 2026 qtr

All shareholding details →

DateClientDealActionQuantityPriceExchange
3 Jan 2024 CHAUHAN TRISHUL JITUSINH Bulk Buy 84,673 81.9300 BSE
3 Jan 2024 CHAUHAN TRISHUL JITUSINH Bulk Sell 84,673 83.2300 BSE
12 Nov 2021 ALPHA LEON ENTERPRISES LLP Bulk Sell 10,926 677.7700 BSE
12 Nov 2021 ALPHA LEON ENTERPRISES LLP Bulk Buy 57,484 621.0000 BSE
30 Sep 2021 WAYS VINIMAY PRIVATE LIMITED Bulk Sell 32,000 349.5500 BSE
5 Aug 2021 WAYS VINIMAY PRIVATE LIMITED Bulk Sell 30,400 370.0500 BSE
2 Aug 2021 WAYS VINIMAY PRIVATE LIMITED Bulk Sell 51,200 331.2500 BSE
28 Jul 2021 SANJAY POPATLAL JAIN Bulk Buy 54,400 282.6400 BSE
14 Jul 2021 LEENA SACHIN SHETTY Bulk Buy 35,200 183.5500 BSE
2 Jul 2021 ROHIT SUNDEEP KARNA Bulk Sell 35,200 113.9700 BSE

All bulk and block deals →

Corporate Announcements

All 3 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
1 Oct 2026 AGM/EGM ANG Lifesciences India Ltd - 540694 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
30 Sep 2026 AGM/EGM ANG Lifesciences India Ltd - 540694 - Shareholder Meeting / Postal Ballot-Outcome of AGM
30 Sep 2026 Company Update ANG Lifesciences India Ltd - 540694 - Announcement under Regulation 30 (LODR)-Change in Management

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

Data unavailable.

Weaknesses

  • Low Return on Equity (-8.6%)
  • Thin net profit margin (4.8%)
  • High financial leverage (Debt/Equity 1.47)
  • Tight liquidity (Current Ratio 0.97)
  • Declining revenue YoY (-43.1%)

Opportunities

Data unavailable.

Threats

  • Weak interest coverage (-0.3x) -- limited cushion against rising rates

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about ANG Lifesciences India Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.